Technical & News Articles about Deargen
Deargen Presented a self-developed small-molecule lead optimization model, MolEQ (Molecule Equalizer) at the Advancing Precision Medicine Drug Development : Incorporation of Real-World Data and Other Novel Strategies Special Conference which was held from AACR on January 9 – 12.
Read More
디어젠(주)는 자체 개발한 저분자화합물 선도물질 최적화 (lead optimization) 인공지능 모델 molecule equalizer (MolEQ) 을 2020년 1월 9일-1월 12일간 American Association for Cancer Research (AACR)에서 주최한 Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies Special Conference에서 포스터 발표했습니다.
Read More
디어젠의 인공지능 기술을 통해, 고형암을 유발하는 핵심 신규 타깃을 찾고 이에 따른 신약후보물질을 도출하는 과정을 소개합니다.
Deargen Presented a world-class drug-protein interaction prediction model, MT-DTI (Molecule Transformer Drug Target Interaction Model). This research is published in the Journal of Machine Learning Research (JMLR).
Read More
디어젠(주)는 세계 최고 수준의 약물-단백질 상호작용 예측 모델 MT-DTI 대해서 발표했습니다. 연구 결과는 JMLR(Journal of Machine Learning Research)저널에 게재되어 있습니다.
Read More
We introduce DEARGEN’s research results on the model that predicts the primary cancer sites (cancer metastasis prediction) through the gene expression profile (GEP).
Read More
유전자 발현량 (GEP)를 보고, 암 원발부위를 예측(암 전이 예측)하는 모델에 대한 디어젠의 연구 결과를 소개합니다.
Read More
Deargen has announced the research results on an AI technology CWx that can discover biomarkers on disease prognosis. The research achievements has been published in the journal Frontiers in Genetics.
Read More
Deargen has announced research results on an AI technology Wx that can discover novel biomarkers. Research achievements are being published in the journal of the Nature Scientific Report, and two inventions related to these have been patented.
Read More
디어젠(주)는 질병의 예후에 관한 바이오마커를 발굴할 수 있는 AI기술 CWx에 대한 연구성과를 발표했습니다. 연구 성과는 Frontiers in Genetics 저널에 게재되어 있습니다.
Read More